Development of transducible artificial transcription factor therapeutics (TAFTs): A new generation of drugs for ophthalmic disorders.

• Research unit: INNOSUISSE
• Project number: 15807.1;9 PFLS-LS

Short description (German)

Development of transducible artificial transcription factor therapeutics (TAFTs): A new generation of drugs for ophthalmic disorders.

Short description (English)

Development of transducible artificial transcription factor therapeutics (TAFTs): A new generation of drugs for ophthalmic disorders.

Abstract (German)

The proposed CTI project aims to develop TAFTs for the treatment of ophthalmic diseases such as retinal vascular diseases, glaucoma and age-related macula degeneration. TAFTs are a new class of biologics modulating gene expression. They are designed to target expression of specific receptor proteins connected to the pathophysiology of eye diseases. The project is expected to bring TAFTs from the preclinical to the clinical stage, thus strenghening Aliophtha's TAFT pipeline.

Abstract (English)

The proposed CTI project aims to develop TAFTs for the treatment of ophthalmic diseases such as retinal vascular diseases, glaucoma and age-related macula degeneration. TAFTs are a new class of biologics modulating gene expression. They are designed to target expression of specific receptor proteins connected to the pathophysiology of eye diseases. The project is expected to bring TAFTs from the preclinical to the clinical stage, thus strenghening Aliophtha's TAFT pipeline.